# Medline Inc. (MDLN) · Edgar & Edgarette company card

> Medline (MDLN) grew revenue 11.5% in FY2025 to $28.4 billion, operating margin 7.8% against a 1.2% median for surgical & medical instruments & apparatus, equity 27.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 2046386 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/MDLN) · [JSON](https://www.pops4.com/boards/company/MDLN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $28.4B |
| Revenue growth, 1 year | 11.5% |
| Revenue growth per year | 10.6% |
| Operating margin | 7.8% (prior year 8.4%) |
| Net margin | 4.1% |
| Operating cash flow | $1.7B |
| Capital spending | $447M |
| Free cash flow | $1.3B |
| Cash | $1.9B |
| Long-term debt | $12.6B |
| Total assets | $38.5B |
| Total equity | $10.7B |
| Equity ÷ assets | 27.9% |
| Return on equity | 10.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 2.37 (grey zone)
- Piotroski F: 6 of 9 (solid)
- Beneish M: -2.39 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $28.4B (FY2025), total debt $12.6B. Experience: revenue up 11.5% on the year, up 10.6% a year over 2 years; operating margin 7.8%, down from 8.4%. Soundness: equity 27.9% of assets, return on equity 10.8%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $25.0B and $35.8B next year (method v3, set from 1,471 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 7.8% against a 1.2% median; growth 11.5% against 11.6%.

Range logged 2026-10-16, receipt 9d1b93bfa5f75060, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-15 ([filing](https://www.sec.gov/Archives/edgar/data/2046386/000110465926116255/0001104659-26-116255-index.htm))

## Recent filings

- 8-K · filed 2026-11-18 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2046386/000119312526467193/0001193125-26-467193-index.htm)
- S-1 · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/2046386/000119312526461946/0001193125-26-461946-index.htm)
- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/2046386/000204638626000063/0002046386-26-000063-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/2046386/000204638626000060/0002046386-26-000060-index.htm)
- 8-K · filed 2026-10-21 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/2046386/000110465926117844/0001104659-26-117844-index.htm)
- 8-K · filed 2026-10-15 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/2046386/000110465926116255/0001104659-26-116255-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0002046386.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2046386

## Cite

POPS4, Edgar & Edgarette: Medline Inc. (MDLN) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/MDLN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

